Summary
Mitoxantrone (1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yap NY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP: Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Int Med 95:694–697, 1981
Stuart-Harris RC, Smith IE: Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumors. Cancer Chemother Pharmacol 8: 179–182, 1982
Coltman CA, McDaniel TM, Balcerzak SP, Morrison FS, and Von Hoff DD: Mitoxantrone hydrochloride (NSC 310739) in lymphoma. A Southwest Oncology Group Study. Invest N Drugs 1:65–70, 1983
Paciucci PA, Ohnuma T, Cuttner J, and Holland JF: Mitoxantrone in refractory acute leukemia. Proc 13th International Congress of Chemother, Vienna, Austria, August, 1983, 212 (Symposium Mitoxantrone) pp. 43–46
Billingham ME, Mason JW, Bristow MR, and Daniels JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865–872, 1978
Unverferth DV, Unverferth BJ, Balcerzak SP, Bashore TA, and Neidhart JA: Cardiac evaluation of mitoxantrone. Cancer Treat Rep 67:343–350, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aapro, M.S., Alberts, D.S. Phase II trial of mitoxantrone in head and neck cancer. Invest New Drugs 2, 329–330 (1984). https://doi.org/10.1007/BF00175386
Issue Date:
DOI: https://doi.org/10.1007/BF00175386